JUMP TO A TOPIC
More About Mesothelioma Specialist Dr. Richard Alexander
Dr. Alexander is the Chief of Surgical Oncology at Rutgers Cancer Institute, with a focus on peritoneal mesothelioma. Aside from his work at Rutgers, the most interesting aspect of Dr. Alexander’s experience is in the military.
He started his medical career as a medical officer in the United States Navy, where he served aboard both the USS Mt. Whitney (LCC-20) and the USS Midway (CV-41).
His titles at Rutgers Cancer Institute include:
- Chief Surgical Officer
- System Director of Surgical Oncology at RWJBarnabas Health
- Regional Director of Surgery for Monmouth Medical Center, affiliated with RWJBarnabas Health
- Medical Officer for U.S. Navy
- Fellowship in Surgical Oncology at Memorial Sloan Kettering Cancer Center in New York City
- Memberships in the American College of Surgeons, American Surgical Association, Society of Surgical Oncology and Royal College of Surgeons (Glasgow)
- Served on multiple committees for the Society of Surgical Oncologists
Get Connected to Dr. H. Richard Alexander
Dr. H. Richard Alexander is Chief of Surgical Oncology at one of the top cancer centers in the United States northeast region. His clinical focus of gastrointestinal surgical oncology includes peritoneal mesothelioma, treated by HIPEC.
Why Choose Dr. Alexander?
- Military service as a medical officer for U.S. Navy
- HIPEC surgery specialist for peritoneal mesothelioma
- Award-winning doctor at a prestigious hospital
HIPEC Surgery Experience
Dr. Alexander can perform HIPEC surgery for peritoneal mesothelioma. HIPEC stands for hyperthermic/heated intraperitoneal chemotherapy. It leads to survival times of 3-4 years.
The specialist conducted a review of 211 patients treated with HIPEC, cytoreduction and adjuvant therapy. The median survival was more than five years.
He published more than 250 peer-review articles and is an editorial board member for the journal “Surgery.”
Military Connection for Veterans With Mesothelioma
Finding a mesothelioma doctor with military experience is rare. This makes Dr. Alexander an asset for veterans with peritoneal surface malignancies.
Doctors from a military background are more skilled at communicating with veterans and their families. They may be able to explain how asbestos exposure occurred.
Following Dr. Alexander’s military service and medical training, he joined the surgical team at the National Cancer Institute. He became a Deputy Director in the Center for Cancer Research.
He later joined the Department of Surgery at the University of Maryland School of Medicine, leading teams developing highly regarded clinical programs for cancer.
Investigation of PD-L1 Expression in Peritoneal Mesothelioma
Dr. Alexander and his team recently looked into PD-L1 expression on peritoneal mesothelioma tumors. They looked at 20 patients and reported 75% overexpressed this protein.
The next step is testing immune checkpoint inhibitors, a type of immunotherapy. Opdivo and Yervoy are in clinical trials for peritoneal mesothelioma. These immunotherapies may slow the growth of tumors by blocking PD-L1 and helping the immune system.
Meeting Dr. Alexander for Consultation
Dr. Richard Alexander sees patients at two locations: Rutgers Cancer Institute and Monmouth Medical Center. He has research and treatment interest in peritoneal mesothelioma.
Patients in the northeast should consider Dr. Alexander as their choice of doctor. Even patients not in this region may consider traveling to see him. If interested, please email nurse and patient advocate Karen Ritter (firstname.lastname@example.org). You can get a list of doctors who can handle your case by filling out our free Doctor Match form and getting our recommendations based on your type of mesothelioma.
Sources & Author
- Richard Alexander, Jr., MD, FACS. RWJBarnabas Health. Retrieved from: https://www.cinj.org/h-richard-alexander-jr-md-facs. Accessed: 01/24/2022.
- Exploring PD-L1 Expression in Malignant Peritoneal Mesothelioma. RWJBarnabas Health. Retrieved from: https://www.cinj.org/exploring-pd-l1-expression-malignant-peritoneal-mesothelioma. Accessed: 01/24/2022.